Chromosome 5p Gain in Cervical Cancer and Its Implications
Author Information
Author(s): Scotto Luigi, Narayan Gopeshwar, Nandula Subhadra V, Subramaniyam Shivakumar, Kaufmann Andreas M, Wright Jason D, Pothuri Bhavana, Mansukhani Mahesh, Schneider Achim, Arias-Pulido Hugo, Murty Vundavalli V
Primary Institution: Columbia University Medical Center
Hypothesis
The increased dosage of chromosome 5p may result in deregulation of genes that confer oncogenic properties to cervical cancer cells.
Conclusion
The study identifies chromosome 5p gain as a critical genetic alteration in cervical cancer, highlighting potential biomarkers and therapeutic targets.
Supporting Evidence
- 63% of invasive cervical cancer cases showed copy number increase of chromosome 5p.
- Identification of Drosha as a key target gene over-expressed due to 5p gain.
- 5p gain is associated with late stages of cervical cancer progression.
- Integration of genomic and expression data provides insights into tumor biology.
- Potential for developing biomarkers and therapeutic targets based on 5p gene alterations.
Takeaway
Researchers found that a part of chromosome 5 is often duplicated in cervical cancer, which may help doctors find new ways to treat the disease.
Methodology
The study used SNP arrays, FISH, and gene expression analyses on various cervical cancer specimens.
Potential Biases
Potential biases in sample selection and analysis methods may affect the results.
Limitations
The study does not establish direct clinical outcomes associated with the identified genetic alterations.
Participant Demographics
The study included 219 specimens from various stages of cervical cancer, including primary tumors and cell lines.
Statistical Information
P-Value
p<0.05
Confidence Interval
90%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website